Burjeel Holdings & OncoHelix unite to set up new laboratory in Abu Dhabi

Burjeel Holdings & OncoHelix unite to set up new laboratory in Abu Dhabi

Burjeel Holdings, the leading healthcare service provider in MENA, has partnered with OncoHelix in order to establish a cutting-edge laboratory in Abu Dhabi to provide advanced molecular genetics, cellular, and immunological profile testing to patients in the UAE.

Through this exclusive agreement, Burjeel Holdings and OncoHelix strive to bring personalized medicine to clinics and hospitals in the UAE.

OncoHelix, based in Western Canada, has the largest breadth of clinically validated comprehensive genomic profiling (CGP) panels for cancer in the country.

Mr. John Sunil

CEO – Burjeel Holdings “Burjeel Holdings continues to invest in and establish new partnerships that help promote the expansion of our translational research program and improve patient outcomes. This new venture will utilize the clinical & academic experience of OncoHelix Inc to build a state-of-the-art laboratory, through which we will offer testing services not widely available in the UAE. Through this agreement, we hope to solidify our position as a leading provider of complex care in the UAE and increase our capabilities to serve the country’s growing medical tourism market. Collaborations like these will benefit the UAE as it transforms into a global leader in healthcare.”

The new lab will be divided into two areas. An advanced diagnostic lab arm will focus